EODData

MEMBERSHIP REGISTER LOG IN

FRA, I54: BIOCYTOGEN PHARMA. H YC1

21 Aug 2026
LAST:

6.950

CHANGE:
 0.40		OPEN:
6.850		HIGH:
6.950		ASK:
0.000		VOLUME:
0
CHG(%):
6.11		PREV:
6.550		LOW:
6.850		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Aug 266.8506.9506.8506.9500
20 Aug 266.6006.6006.4506.5500
19 Aug 266.5506.5506.5506.5500
18 Aug 266.8506.8506.8506.8500
17 Aug 266.8506.9006.8506.8500
14 Aug 267.5007.5507.5007.5500
13 Aug 267.7007.7007.6007.6000
12 Aug 267.2007.2507.2007.2500
07 Aug 266.6006.7506.6006.7500
06 Aug 266.0506.0506.0006.0500

PROFILE

Name:BIOCYTOGEN PHARMA. H YC1
About:Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4-tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Sector:Healthcare
Industry:Biotechnology
Address:12 Baoshen South Street, Beijing, China
Website:https://www.biocytogen.com
ISIN:CNE100005D27

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:115.83 
Price to Sales:1.97 
Price to Book:10.63 
Profit Margin:0.19 
Operating Margin:0.31 
Return on Assets:0.07 
Return on Equity:0.19 
Revenue:198.61M 
EBITDA:416.49M 
Shares:108.27M 
Market Cap:752.49M 

TECHNICAL INDICATORS

MA5:6.753.0%
MA10:6.900.8%
MA20:6.349.7%
MA50:5.5724.7%
MA100:5.6522.9%
MA200:4.9640.2%
STO9:34.78
STO14:65.91
RSI14:69.88 
WPR14:-30.95
MTM14:1.45
ROC14:0.26 
ATR:0.33 
Week High:7.558.6%
Week Low:6.457.8%
Month High:7.7010.8%
Month Low:5.3040.2%
Year High:7.7010.8%
Year Low:2.34197.6%
Volatility:61.66